rifalazil

rifalazil

Infectious disease A rifampin derivative effective against TB, which has a longer T1⁄2 and intracellular concentrations, allowing shorter treatment, fewer doses, better Pt compliance. See Rifampin.
Mentioned in ?
References in periodicals archive ?
Drug Profiles discussed in this report include BDNA-003, chlamydia trachomatis vaccine, chlamydia vaccine, minocycline Gel, rifalazil.
Rifalazil is currently in clinical development with Phase I and Phase II trials underway or planned for several indications.
The assets consisted of 1) Rifalazil, a Phase II antibiotic, 2) a library of novel rifamycin compounds, and 3) a clinical stage superoxide dismutase mimetic (SODm) and a library of SODm small molecules.
This brings the total number to 15 US patents covering rifalazil and its use for treating bacterial infections.
Rifalazil and rifaximin were the most potent agents against the strains tested, but resistance to both agents in some isolates was observed.
Rifalazil is the most developed of these compounds, though most of the interest for combination antibiotics has centered on novel compounds or new chemical entities ("NCEs").
10:00 am - 11:30 am: E-1439/164 In Vitro Activity of Ramoplanin, Rifalazil, Rifaximin, Metronidazole, and Vancomycin against 110 Unique Toxigenic Clostridium difficile Clinical Isolates (poster)
Rifalazil, the most potent anti-chlamydial agent that has been administered to people, may provide a better treatment option for Chlamydia STD.
In October, DepoMed announced a memorandum of understanding to develop a controlled-release oral tablet to deliver ActivBiotics' broad-spectrum lead compound, rifalazil, to the gastrointestinal tract, targeting H.
In addition, due to the high volume of requests for due diligence materials from prospective buyers for the purchase of the intellectual property, the Company has created an online datasite that allows access to confidential information pertinent to each of the three assets: Rifalazil, antibacterial NCEs, and superoxide dismutase small molecule mimetics.
The product will be a controlled-release oral tablet which delivers ActivBiotics' broad-spectrum lead compound, rifalazil, to the stomach and gastrointestinal tract.